Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:327253.
doi: 10.1155/2012/327253. Epub 2012 Mar 5.

Castration-resistant prostate cancer: mechanisms, targets, and treatment

Teresa Maria Santos Amaral  1 , Daniela Macedo, Isabel Fernandes, Luis Costa
Affiliations

Castration-resistant prostate cancer: mechanisms, targets, and treatment

Teresa Maria Santos Amaral et al. Prostate Cancer. 2012.

Abstract

Patients with castration-resistant prostate cancer (CRPC), who progress after docetaxel therapy, had until very recently, only a few therapeutic options. Recent advances in this field brought about new perspectives in the treatment of this disease. Molecular, basic, and translational research has given us a better understanding on the mechanisms of CRPC. This great investment has turned into a more rational approach to the development of new drugs. Some of the new treatments are already available to our patients outside clinical trials and may include inhibitors of androgen biosynthesis; new chemotherapy agents; bone-targeted therapy; and immunotherapy. This paper aims to review the mechanisms of prostate cancer resistance, possible therapeutic targets, as well as new options to treat CRPC.

PubMed Disclaimer

References

    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2008. Bethesda, Md, USA: National Cancer Institute; 2011. based on November 2010 SEER data submission, posted to the SEER web site, http://seer.cancer.gov/csr/1975_2008/
    1. Marques RB, Dits NF, Erkens-Schulze S, Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS ONE. 2010;5(10) Article ID e13500. - PMC - PubMed
    1. Attard G, Sarker D, Reid A, Molife R, Parker C, De Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. British Journal of Cancer. 2006;95(7):767–774. - PMC - PubMed
    1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Clinical Practice Urology. 2009;6(2):76–85. - PMC - PubMed
    1. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clinical Cancer Research. 2009;15(10):3251–3255. - PubMed

LinkOut - more resources